Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

The potential benefit of SGLT2 inhibitors in metabolic syndrome is with prediabetic stage unclear. This work was undertaken to investigate the non-glycemic effect of empagliflozin on metabolic syndrome rats wi...

Source: Cardiovascular Diabetology - November 11, 2016 Category: Cardiology Authors: Hiroaki Kusaka, Nobutaka Koibuchi, Yu Hasegawa, Hisao Ogawa and Shokei Kim-Mitsuyama Source Type: research